Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance PRINCETON, N.J. / Oct 09, 2024 / Business Wire / UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan... Read More